SCHEMBL1209124

SCHEMBL1209124

CC(C)(C)N(C(=O)O)c1ccccc1CI

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 4/20 0.36
KMT2A Q03164 4/20 0.36
HTT P42858 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
AKT1 P31749 1/20 0.35
RIPK1 Q13546 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HIF1A Q16665 1/20 0.33
LMNA P02545 2/20 0.33
ALDH1A1 P00352 2/20 0.33
TRPM8 Q7Z2W7 1/20 0.33
KDM4E B2RXH2 1/20 0.33
PTPN1 P18031 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
RECQL P46063 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1208112 0.85 MEN1 (0.37) MEN1KMT2AHTTL3MBTL1RIPK1
SCHEMBL20564934 0.83 KMT2A (0.36) MEN1KMT2AHTTL3MBTL1RIPK1
SCHEMBL1974011 0.81 KMT2A (0.38) MEN1KMT2AHTTL3MBTL1RIPK1
SCHEMBL21046003 0.80 IDO1 (0.42) MEN1KMT2AHTTL3MBTL1
SCHEMBL6005339 0.75 TRPM8 (0.46) MEN1KMT2AHTTL3MBTL1CYP3A4
SCHEMBL2116911 0.74 PDCD1 (0.44) MEN1KMT2AHTTL3MBTL1LMNA
SCHEMBL28449626 0.74 L3MBTL1 (0.42) MEN1KMT2AHTTL3MBTL1CYP2C19
SCHEMBL247809 0.74 KDM4E (0.38) MEN1KMT2AHTTL3MBTL1RIPK1
SCHEMBL2115046 0.73 LMNA (0.33) MEN1KMT2AHTTL3MBTL1AKT1
SCHEMBL16968516 0.72 TACR1 (0.47) MEN1KMT2ASMN1; SMN2ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110046105-A1 Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof SANOFI-AVENTIS (FR) 2011-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110046105-A1 Heterocycle-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising them and use thereof GIPR, DDC, PGC MEN1 2371/4885KMT2A 2642/4885HTT 1571/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.